The Covid Management Guidelines India Group is a collection of senior expert clinicians, academics and methodologists in reputed institutions nationally, led by the Christian Medical College Vellore in partnership with the Clinical Infectious Diseases Society of India (CIDS). We are supported by methodologists at the Prof BV Moses Centre for Evidence Informed Healthcare and the Cochrane Infectious Diseases Group.

We are using a rigorous evidence-based approach to make guidelines to support clinicians managing patients with COVID-19 in secondary and tertiary care settings in India. Prioritised management interventions are each subjected to systematic evidence review, followed by application of GRADE methodology by experts in the field to appraise the evidence and interpret the intervention’s place in an Indian context. As each recommendation or clinical practice guideline is ready, it will appear on this website in a modular fashion, enabling immediate use by clinicians.


Sarilumab (29th November 2021)

Itolizumab (22nd November 2021)

Prone Positioning (05th November 2021)

Convalescent Plasma (27th October 2021)

Azithromycin (27th September 2021)

Baricitinib (17th September 2021)

Colchicine (3rd September 2021)

Casirivimab – Imdevimab (11th August 2021)

Non-invasive ventilation (NIV) vs High flow nasal oxygen (HFNO) (27th July 2021)

Favipiravir (19th July 2021)

Systemic Corticosteroids (15th July 2021)

Prophylactic vs Therapeutic dose anticoagulation (29th June 2021)

Inhaled Corticosteroids (21st June 2021)

Remdesivir (1st June 2021)

Tocilizumab (24th May 2021)

Ivermectin (15th May 2021)